作者
Allison W Kurian, Kevin C Ward, Nadia Howlader, Dennis Deapen, Ann S Hamilton, Angela Mariotto, Daniel Miller, Lynne S Penberthy, Steven J Katz
发表日期
2019/5/20
期刊
Journal of Clinical Oncology
卷号
37
期号
15
页码范围
1305-1315
出版商
American Society of Clinical Oncology
简介
PURPOSE
Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer.
METHODS
The study included all women 20 years of age or older diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014 and reported to the SEER registries covering the entire state populations. SEER data were linked to results from four laboratories that performed nearly all germline cancer genetic testing. Testing use and results were analyzed at the gene level.
RESULTS
There were 77,085 patients with breast cancer and 6,001 with ovarian cancer. Nearly one quarter of those with breast cancer (24.1%) and one third of those with ovarian cancer (30.9%) had genetic test results. Among patients with ovarian cancer, testing was lower in blacks (21.6%; 95% CI, 18.1% to 25.4%; v whites, 33.8%; 95% CI …
学术搜索中的文章
AW Kurian, KC Ward, N Howlader, D Deapen… - Journal of Clinical Oncology, 2019